(2026). TOMM40/FADS2 Expression Ratio Predicts the Sensitivity to mTOR Inhibitors in Triple‐Negative Breast Cancer. Cancer Medicine.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"TOMM40/FADS2 Expression Ratio Predicts the Sensitivity to MTOR Inhibitors in Triple‐Negative Breast Cancer."
Cancer Medicine 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"TOMM40/FADS2 Expression Ratio Predicts the Sensitivity to MTOR Inhibitors in Triple‐Negative Breast Cancer."
Cancer Medicine, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.